FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096275800> ?p ?o ?g. }

• W3096275800 endingPage "2297.e0" @default.
• W3096275800 startingPage "2289" @default.
• W3096275800 abstract "Purpose Ivabradine reduces heart rate (HR) in patients with heart failure (HF). However, its effect on cardiac remodeling is not obvious. The goal of this study was to explore the extra effect of ivabradine on cardiac remodeling in patients with HF. Methods We searched PubMed from database inception to January 31, 2020, Cochrane and Embase from database inception to February 2, 2020, and Web of Science and ClinicalTrials.gov from database inception to February 3, 2020, for randomized controlled trials on ivabradine treatments in patients with stable symptomatic HF, left ventricular ejection fraction (LVEF) < 45%, and resting HR ≥ 60 beats/min in sinus rhythm. We pooled the mean differences (MDs) or standardized mean differences and their 95% CIs. An inverse variance was used to combine data. Fixed- or random-effects models were used to outline the outcomes based on heterogeneity levels. We assessed the heterogeneity among studies according to the I2 statistic. A sensitivity analysis for select results was performed to assess the robustness of the outcomes. Findings Of 2277 trials, 9 trials fulfilled the inclusion criteria. A total of 1523 patients were enrolled in 9 studies. There were 796 participants in the ivabradine group and 727 participants in the control group. The duration of follow-up ranged from 6 weeks to 19.6 months. The mean (SD) age of the participants was 59.7 (11.2) years, and 1187 participants (77.9%) were men. Therapy with ivabradine was related to reversing cardiac remodeling with a significant increase in LVEF (MD = 3.04%; 95% CI, 2.07%–4.00%; p < 0.001), decrease in the left ventricular end-systolic volume index (LVESVI) (MD = −7.30 mL/m2; 95% CI, −12.94 to −1.66 mL/m2; p = 0.01), and reduction in the left ventricular end-diastolic volume index (LVEDVI) (MD = −7.27 mL/m2; 95% CI, −14.04 to −0.50 mL/m2; p = 0.04). In the subgroup of enrolled patients with a resting HR of ≥70 beats/min, greater progress in LVEF was detected in the ivabradine group (MD = 3.60%; 95% CI, 2.40%–4.81%; p < 0.001), and a higher improvement in LVESVI was identified in the ivabradine group (MD = −11.06 mL/m2; 95% CI, −21.15 to −0.98 mL/m2; p = 0.03). Implications In patients with stable symptomatic HF, LVEF <45%, and resting HR ≥ 60 beats/min in sinus rhythm, ivabradine use was associated with reversing cardiac remodeling with a significant increase in LVEF, a decrease in LVESVI, and a reduction in LVEDVI." @default.
• W3096275800 created "2020-11-09" @default.
• W3096275800 creator A5000147729 @default.
• W3096275800 creator A5050565030 @default.
• W3096275800 creator A5078904473 @default.
• W3096275800 creator A5079348232 @default.
• W3096275800 date "2020-12-01" @default.
• W3096275800 modified "2023-10-16" @default.
• W3096275800 title "Effects of Ivabradine on Cardiac Remodeling in Patients With Stable Symptomatic Heart Failure: A Systematic Review and Meta-analysis" @default.
• W3096275800 cites W1966200033 @default.
• W3096275800 cites W1989036742 @default.
• W3096275800 cites W2004114486 @default.
• W3096275800 cites W2018984462 @default.
• W3096275800 cites W2019468355 @default.
• W3096275800 cites W2046746746 @default.
• W3096275800 cites W2048703304 @default.
• W3096275800 cites W2052780003 @default.
• W3096275800 cites W2062837386 @default.
• W3096275800 cites W2063990451 @default.
• W3096275800 cites W2068810785 @default.
• W3096275800 cites W2079156987 @default.
• W3096275800 cites W2080011884 @default.
• W3096275800 cites W2088091502 @default.
• W3096275800 cites W2089365655 @default.
• W3096275800 cites W2089440917 @default.
• W3096275800 cites W2115071060 @default.
• W3096275800 cites W2115107692 @default.
• W3096275800 cites W2119061468 @default.
• W3096275800 cites W2128597526 @default.
• W3096275800 cites W2134833483 @default.
• W3096275800 cites W2136642260 @default.
• W3096275800 cites W2170675714 @default.
• W3096275800 cites W2309526292 @default.
• W3096275800 cites W2315673735 @default.
• W3096275800 cites W2342371138 @default.
• W3096275800 cites W2415172968 @default.
• W3096275800 cites W2463195288 @default.
• W3096275800 cites W2758818102 @default.
• W3096275800 cites W2789166812 @default.
• W3096275800 cites W2805240824 @default.
• W3096275800 cites W2883985832 @default.
• W3096275800 cites W2889211151 @default.
• W3096275800 cites W2906985222 @default.
• W3096275800 cites W2914073144 @default.
• W3096275800 cites W2951939172 @default.
• W3096275800 cites W2965210714 @default.
• W3096275800 cites W4232767515 @default.
• W3096275800 cites W4253854553 @default.
• W3096275800 cites W86846889 @default.
• W3096275800 doi "https://doi.org/10.1016/j.clinthera.2020.10.005" @default.
• W3096275800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33160681" @default.
• W3096275800 hasPublicationYear "2020" @default.
• W3096275800 type Work @default.
• W3096275800 sameAs 3096275800 @default.
• W3096275800 citedByCount "3" @default.
• W3096275800 countsByYear W30962758002021 @default.
• W3096275800 countsByYear W30962758002022 @default.
• W3096275800 countsByYear W30962758002023 @default.
• W3096275800 crossrefType "journal-article" @default.
• W3096275800 hasAuthorship W3096275800A5000147729 @default.
• W3096275800 hasAuthorship W3096275800A5050565030 @default.
• W3096275800 hasAuthorship W3096275800A5078904473 @default.
• W3096275800 hasAuthorship W3096275800A5079348232 @default.
• W3096275800 hasConcept C126322002 @default.
• W3096275800 hasConcept C164705383 @default.
• W3096275800 hasConcept C168563851 @default.
• W3096275800 hasConcept C2776034619 @default.
• W3096275800 hasConcept C2777953023 @default.
• W3096275800 hasConcept C2778198053 @default.
• W3096275800 hasConcept C2779167562 @default.
• W3096275800 hasConcept C535046627 @default.
• W3096275800 hasConcept C71924100 @default.
• W3096275800 hasConcept C78085059 @default.
• W3096275800 hasConcept C84393581 @default.
• W3096275800 hasConcept C95190672 @default.
• W3096275800 hasConceptScore W3096275800C126322002 @default.
• W3096275800 hasConceptScore W3096275800C164705383 @default.
• W3096275800 hasConceptScore W3096275800C168563851 @default.
• W3096275800 hasConceptScore W3096275800C2776034619 @default.
• W3096275800 hasConceptScore W3096275800C2777953023 @default.
• W3096275800 hasConceptScore W3096275800C2778198053 @default.
• W3096275800 hasConceptScore W3096275800C2779167562 @default.
• W3096275800 hasConceptScore W3096275800C535046627 @default.
• W3096275800 hasConceptScore W3096275800C71924100 @default.
• W3096275800 hasConceptScore W3096275800C78085059 @default.
• W3096275800 hasConceptScore W3096275800C84393581 @default.
• W3096275800 hasConceptScore W3096275800C95190672 @default.
• W3096275800 hasIssue "12" @default.
• W3096275800 hasLocation W30962758001 @default.
• W3096275800 hasOpenAccess W3096275800 @default.
• W3096275800 hasPrimaryLocation W30962758001 @default.
• W3096275800 hasRelatedWork W1982732353 @default.
• W3096275800 hasRelatedWork W2025203805 @default.
• W3096275800 hasRelatedWork W2038962385 @default.
• W3096275800 hasRelatedWork W2046961793 @default.
• W3096275800 hasRelatedWork W2162221761 @default.
• W3096275800 hasRelatedWork W2189032557 @default.
• W3096275800 hasRelatedWork W2381773918 @default.

• next